Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Aprea Therapeutics, Inc. (APRE)
Company Research
Source: GlobeNewswire
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitorEmerging clinical proof of concept responses without class-limiting toxicity to date support Aprea’s development strategy of differentiated WEE1 inhibition with an improved therapeutic indexA further update from the trial is expected in the second quarter of 2026 DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the confirmation of a partial response (PR) in its ongoing ACESOT-1051 trial evaluating APR-1051, a potent and selective WEE1 kinase inhibitor. The confirmed PR was observed in a patient with PPP2R1A-mutated endometrial cancer who is curre
Show less
Read more
Impact Snapshot
Event Time:
APRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APRE alerts
High impacting Aprea Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
APRE
News
- Frazier Life Sciences Appoints Christian Schade as Senior AdvisorBusiness Wire
- Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private PlacementGlobeNewswire
- Aprea Therapeutics (APRE) had its "outperform" rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- Aprea Therapeutics (APRE) had its price target lowered by HC Wainwright from $4.00 to $1.20. They now have a "buy" rating on the stock.MarketBeat
- Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement [Yahoo! Finance]Yahoo! Finance
APRE
Sec Filings
- 4/7/26 - Form SCHEDULE
- 4/1/26 - Form SCHEDULE
- 4/1/26 - Form 4
- APRE's page on the SEC website